PD-L1 PET/CT imaging shows partial tumor saturation during atezolizumab treatment

被引：0
|
作者：
Smit, L. M. [1 ]
Hooiveld, J. [1 ]
van de Donk, P. P. [1 ]
de Ruijter, L. Kist [1 ]
Kok, I. C. [1 ]
Winkel, C. A. J. [1 ]
Giesen, D. [2 ]
Lub-de Hooge, M. N. [3 ]
Brouwers, A. H. [2 ]
Oosting, S. F. [4 ]
Bensch, F. [5 ]
Schroder, C. P. [1 ]
Jalving, M. [1 ]
Elias, S. G. [6 ]
Gietema, J. A. [1 ]
Deurloo, R. J. [7 ]
Williams, S. P. [8 ]
Ungewickell, A. [9 ]
De Groot, D. J. A. [1 ]
de Vries, E. G. E. [1 ]
机构：
[1] Univ Med Ctr Groningen, Med Oncol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Nucl Med & Mol Imaging, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, Groningen, Netherlands
[4] Univ Med Ctr Groningen, Med Oncol, Groningen, Netherlands
[5] Univ Med Ctr Groningen, Pulm Dis, Groningen, Netherlands
[6] Univ Med Ctr Utrecht, Epidemiol & Hlth Econ, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[7] F Hoffmann La Roche Ltd, Translat Med Oncol, Basel, Switzerland
[8] Genentech Inc, Biomed Imaging Res Biol, San Francisco, CA USA
[9] Genentech Inc, Clin Dev Hematol Oncol, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB248
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [41] Imaging PD-L1 Expression with ImmunoPET
    Truillet, Charles
    Oh, Hsueh Ling J.
    Yeo, Siok Ping
    Lee, Chia-Yin
    Huynh, Loc T.
    Wei, Junnian
    Parker, Matthew F. L.
    Blakely, Collin
    Sevillano, Natalia
    Wang, Yun-Hua
    Shen, Yuqin S.
    Olivas, Victor
    Jami, Khaled. M.
    Moroz, Anna
    Jego, Benoit
    Jaumain, Emilie
    Fong, Lawrence
    Craik, Charles S.
    Chang, Albert J.
    Bivona, Trever G.
    Wang, Cheng-I
    Evans, Michael J.
    BIOCONJUGATE CHEMISTRY, 2018, 29 (01) : 96 - 103
  • [42] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
  • [43] Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
    Zhang, Xiaoqing
    Cheng, Chen
    Hou, Jiyan
    Qi, Xinyue
    Wang, Xin
    Han, Ping
    Yang, Xuanming
    CELLULAR & MOLECULAR IMMUNOLOGY, 2019, 16 (04) : 392 - 400
  • [44] Immuno PET imaging of PD-L1 expression in syngeneic and human xenograft tumor mouse models using a site-specific 89Zr labeled PD-L1 antibody
    Christensen, Camilla
    Kristensen, Lotte K.
    Toftevall, Hanna
    Nordgren, Maria
    Agnew, Brian J.
    Nielsen, Carsten H.
    Kjaer, Andreas
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients
    Liu, Yuting
    Zugazagoitia, Jon
    Henick, Brian
    Schalper, Kurt A.
    Rimm, David L.
    CANCER RESEARCH, 2019, 79 (13)
  • [46] A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody
    Qin, Songbing
    Yu, Yang
    Guan, Hui
    Yang, Yanling
    Sun, Fenghao
    Sun, Yan
    Zhu, Jiaxing
    Xing, Ligang
    Yu, Jinming
    Sun, Xiaorong
    AGING-US, 2021, 13 (09): : 13006 - 13022
  • [47] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
    Liu, Y.
    Cao, L.
    Che, X.
    Qiu, X.
    Li, Z.
    Yang, B.
    Wang, S.
    Qu, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
  • [48] PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
    Cimadamore, Alessia
    Massari, Francesco
    Santoni, Matteo
    Lopez-Beltran, Antonio
    Cheng, Liang
    Scarpelli, Marina
    Montironi, Rodolfo
    Moch, Holger
    CURRENT DRUG TARGETS, 2020, 21 (16) : 1664 - 1671
  • [49] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [50] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
12345